Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Silence Therapeutics (SLN) EBITDA Margin (2024 - 2025)

Silence Therapeutics (SLN) has disclosed EBITDA Margin for 2 consecutive years, with 166076.47% as the latest value for Q4 2025.

  • Quarterly EBITDA Margin rose 16588737.0% to 166076.47% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 4140.19% through Dec 2025, down 411452.0% year-over-year, with the annual reading at 3962.43% for FY2025, 393674.0% down from the prior year.
  • EBITDA Margin hit 166076.47% in Q4 2025 for Silence Therapeutics, up from 16505.66% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 166076.47% in Q4 2025 to a low of 20006.34% in Q1 2025.